DK0498718T3 - Anvendelse af 4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridinderivater som indfangere af frie radikaler - Google Patents

Anvendelse af 4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridinderivater som indfangere af frie radikaler

Info

Publication number
DK0498718T3
DK0498718T3 DK92400289.2T DK92400289T DK0498718T3 DK 0498718 T3 DK0498718 T3 DK 0498718T3 DK 92400289 T DK92400289 T DK 92400289T DK 0498718 T3 DK0498718 T3 DK 0498718T3
Authority
DK
Denmark
Prior art keywords
free radical
radical scavengers
compounds
trifluoromethylphenyl
formula
Prior art date
Application number
DK92400289.2T
Other languages
Danish (da)
English (en)
Inventor
Michel Heaulme
Umberto Guzzi
Original Assignee
Sanofi Elf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Elf filed Critical Sanofi Elf
Application granted granted Critical
Publication of DK0498718T3 publication Critical patent/DK0498718T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK92400289.2T 1991-02-05 1992-02-05 Anvendelse af 4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridinderivater som indfangere af frie radikaler DK0498718T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9101283A FR2672213B1 (fr) 1991-02-05 1991-02-05 Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.

Publications (1)

Publication Number Publication Date
DK0498718T3 true DK0498718T3 (da) 1994-12-05

Family

ID=9409370

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92400289.2T DK0498718T3 (da) 1991-02-05 1992-02-05 Anvendelse af 4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridinderivater som indfangere af frie radikaler

Country Status (13)

Country Link
US (1) US5292745A (es)
EP (1) EP0498718B1 (es)
JP (1) JP3471820B2 (es)
AT (1) ATE109467T1 (es)
AU (1) AU649099B2 (es)
CA (1) CA2060616C (es)
DE (1) DE69200284T2 (es)
DK (1) DK0498718T3 (es)
ES (1) ES2061319T3 (es)
FR (1) FR2672213B1 (es)
HU (2) HU212945B (es)
IE (1) IE66593B1 (es)
MX (1) MX9200485A (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.
FR2740343B1 (fr) * 1995-10-26 1999-01-22 Sanofi Sa Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
BR9611124A (pt) * 1995-10-26 1999-05-11 Sanofi Sa Utilização da 1-(2-naft-2-iletil)-4- (3-trifluorometifenil) -1,2,3,6-tetraidropiridina ou um dos seus sais de adição com ácidos farmaceuticamente aceitáveis composição farmacéutica e método de tratamento da esclerose lateral amiotrófica
FR2763847B1 (fr) * 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
EP1135114B1 (en) * 1998-12-01 2009-01-07 Alexandre T. Rotta Method for reducing free-radical induced injury in vitro
MXPA04001255A (es) * 2001-08-29 2004-05-27 Alcon Inc Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
JP2008504275A (ja) * 2004-06-24 2008-02-14 インサイト・コーポレイション Ｎ−置換ピペリジンおよびその医薬としての使用
NZ551602A (en) * 2004-06-24 2010-11-26 Incyte Corp Amido compounds and their use as pharmaceuticals
US7687665B2 (en) * 2004-06-24 2010-03-30 Incyte Corporation 2-methylprop anamides and their use as pharmaceuticals
US20060009491A1 (en) * 2004-06-24 2006-01-12 Incyte Corporation Amido compounds and their use as pharmaceuticals
EP1778229A4 (en) * 2004-08-10 2009-06-17 Incyte Corp AMID COMPOUNDS AND THEIR USE AS MEDICAMENTS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4691019A (en) * 1981-03-11 1987-09-01 Sanofi Anorectic agent; 4-(3-trifluoromethylphenyl)-1-(2-cyanoethyl)-1,2,3,6-tetrahydropyridine
FR2501682A1 (fr) * 1981-03-11 1982-09-17 Sanofi Sa Trifluoromethylphenylpyridines a activite anorexigene, un procede de preparation et compositions pharmaceutiques en contenant
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
GB2226269B (en) * 1988-12-22 1992-11-25 Zdzislaw Bieganski Cable stripper
FR2650505B1 (fr) * 1989-08-07 1994-06-03 Midy Spa Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
AU1065592A (en) 1992-08-13
EP0498718B1 (fr) 1994-08-03
JPH04312528A (ja) 1992-11-04
ES2061319T3 (es) 1994-12-01
CA2060616C (en) 2004-04-06
IE920354A1 (en) 1992-08-12
HUT62563A (en) 1993-05-28
EP0498718A1 (fr) 1992-08-12
HU9200335D0 (en) 1992-04-28
CA2060616A1 (en) 1992-08-06
JP3471820B2 (ja) 2003-12-02
MX9200485A (es) 1992-11-01
HU211457A9 (en) 1995-11-28
IE66593B1 (en) 1996-01-24
US5292745A (en) 1994-03-08
AU649099B2 (en) 1994-05-12
DE69200284T2 (de) 1995-03-02
FR2672213A1 (fr) 1992-08-07
HU212945B (en) 1996-12-30
DE69200284D1 (de) 1994-09-08
ATE109467T1 (de) 1994-08-15
FR2672213B1 (fr) 1995-03-10

Similar Documents

Publication Publication Date Title
DK0498718T3 (da) Anvendelse af 4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridinderivater som indfangere af frie radikaler
NO20054264L (no) Ikke-Nukleoside Revers Transkriptase-Inhibitorer I for behandling av HIV-medierte sydommer
CA2394327A1 (en) Substituted piperazine and piperidine calcium channel blockers
MXPA05007496A (es) Tienopirimidindionas y su uso en la modulacion de enfermedades autoinmunes.
DE69736642D1 (de) Heterocyclische Verbindungen, ihre Herstellung und Verwendung
NO20072115L (no) Farmasoytiske forbindelser
ATE40368T1 (de) Xanthin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
NO954681L (no) Kjemiske forbindelser
ATE154937T1 (de) Steroide zur behandlung von prostatisch- hypertrophe, ihre herstellung und verwendung
DK0437030T3 (da) Anvendelse af 4-substituerede imidazoler til nedsættelse af det intraoculære tryk
NO20003773L (no) Syklobutenderivater, deres fremstilling og deres terapeutiske anvendelser
NO161174C (no) Analogifremgangsm te ved fremstilling av terapeutisk aktive 1-4 dihydropyridin-derivater.
KR920701178A (ko) 3-아릴옥사졸리디논 유도체, 그의 제조방법 및 그의 치료 용도
ATE152453T1 (de) Guanidinalkyl-1,1-bisphosphonsäurederivate, verfahren zu ihrer herstellung und ihre verwendung
NO812355L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3,1-benzoksazin-2-on-derivater
NO972887L (no) Piperidineddiksyrederivater anvendelige som fibrinogen-antagonistmiddel
HUP0004588A2 (hu) Szubsztituált 1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-ol-származékok, eljárás előállításukra és alkalmazásuk gyógyszerként, valamint a vegyületeket tartalmazó gyógyszerkészítmények
ATE62908T1 (de) Neue derivate von 4,5-dihydro-oxazolen, verfahren zu ihrer herstellung und ihre verwendung.
ES2016017A6 (es) Procedimiento para preparar derivados de acido 1,1-dioxocefem-4-carbotiolico.
ATE42295T1 (de) Penem-derivate, verfahren zu deren herstellung, ihre verwendung und pharmazeutische zusammensetzungen.
ATE96434T1 (de) 2-(heteroalkyl)-1,4-dihydropyridine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE27455T1 (de) Heterocyclische guanidino-phenylamidine, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
NO20030781L (no) Prodrugs til NMDA-reseptor-ligander
NO20010801L (no) Nye 6-amino- eller 6-hydroazino-sulfonyl-3- kinolynylfosfonsyreforbindelse, fremgangsmåte ved deresfremstilling og farmasöytiske sammensetninger inneholdende dem
RU2003105827A (ru) Средства против слабоумия, содержащие производные 2-арил-8-оксодигидропурина, в качестве активного ингредиента